Navigation Links
Who is the arch-criminal in the development of hepatopulmonary syndrome?
Date:12/19/2007

The hepatopulmonary syndrome (HPS) develops when an arterial oxygenation deficiency occurs due to intra-pulmonary vascular dilatations that are often associated with severe hepatic disease. HPS occurs in 15-20% of patients with liver cirrhosis undergoing evaluation for orthotopic liver transplantation. Recent studies support that the presence of HPS significantly increases mortality in cirrhosis, particularly in those with decompensated liver disease.

One of the characteristics of HPS is intra-pulmonary vascular dilatation. The intra-pulmonary vascular dilatation severely affects pulmonary gas exchange, and consequently leads to hypoxia and raised mortality of cirrhotic patients. The present research hotspots focus mainly on clarifying the pathogenesis of HPS, particularly in exploring the mechanism of intra-pulmonary vascular dilatation.

Dr. Hui-Ying Zhang et al. developed a rat model characteristic of cirrhosis and HPS that can be non-invasively induced by multiple pathogenic factors including high fat diet, alcohol, cholesterol, corn flour and CCl4 and demonstrated a significantly increased level of lipopolysaccharide (LPS) in plasma is closely related to the decreased blood oxygen content and intra-pulmonary vascular dilatation. And they further characterized the relation between the progeression and severity of HPS and the degree of hepatic dysfunction, and explored how intestinal endotoxemia (IETM) affects the intra-pulmonary vascular dilatation.

In the research, Dr. Zhang et al. dynamically observed typical histological changes in both liver and lung and found that the progression and severity of HPS were closely associated with increased plasma LPS level, and that there was a paralleling deterioration between the lung function and the hepatic function in the cirrhotic rats. This indicated that HPS is interrelated with underlying liver disease and supported their hypothesis that hepatic pathological alteration is a substantial basis for the development of HPS in cirrhotic rats.

On the other hand , they also observed and found that dynamic alterations of plasma endotoxin were closely associated with increased expression of eNOS, iNOS, HO-1 and increased number of capillaries, which demonstrated that eNOS, iNOS and HO-1 were involved in increased NO and CO production in the lung. The elevated NO resulted preferably from iNOS of pulmonary macrophages and, to a lesser extent, from eNOS in the lung of cirrhotic rats. Both NO and CO are involved in pulmonary vascular abnormalities, and pulmonary macrophages play a role to HPS. They also found that the exhibition of pulmonary vascular abnormalities was not only in vascular dilatation but also in increased number. The results suggest that both NOS/NO and HO-1/CO pathways are contributor to the development of HPS, and that IETM plays a leading role in the development of HPS in the cirrhotic rats.

More interesting, they observed and found a mutual inhibition between NOS/NO and HO-1/CO pathways by using respective inhibitors, and consequently demonstrated that NOS/NO and HO-1/CO pathways may be interrelated in pathogenesis of intra-pulmonary vascular abnormalities in the development of HPS.

In conclusion, it is IETM that is the arch-criminal in the development of hepatopulmonary syndrome. Therefore, the strategy directed against LPS will certainly be effective in the prevention and treatment of HPS.


'/>"/>

Contact: Jing Zhu
j.zhu@wjgnet.com
World Journal of Gastroenterology
Source:Eurekalert

Related medicine news :

1. Isolation of a new gene family essential for early development
2. Therap Services Continues to Hire Experienced Developmental Disability Industry Clinicians for its Customer Support Team
3. The Philadelphia Walk Now for Autism Expected to Draw 10,000 Walkers and Raise $1 Million to Help Find Answers About the Nations Fastest-Growing Developmental Disorder
4. Ovation further advances development pipeline with new phase III epilepsy study
5. Pioneer Surgical Technology Hires Vice President of New Business Development
6. Bridgetech Announces Addition of the Agency for Healthcare Research and Quality as Content Provider in its Development of a Healthcare Web Portal in China
7. Bioniche Receives $2 Million Government Grant For Market Development Related to its E. coli O157:H7 Cattle Vaccine
8. DTI Medical Corporation Announces Reverse Split and Other Corporate Developments
9. Optim To Assist Prairie Community Health Center with Construction Scope Development
10. Nick Childs Joins Grey New York as Director of Content Development
11. New clues to breast cancer development in high-risk women
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/25/2016)... Montreal, Canada (PRWEB) , ... June 25, 2016 , ... ... the pursuit of success. In terms of the latter, setting the bar too high ... low, risk more than just slow progress toward their goal. , Research from ...
(Date:6/24/2016)... ... 2016 , ... June 19, 2016 is World Sickle Cell Observance Day. In ... benefits of holistic treatments, Serenity Recovery Center of Marne, Michigan, has issued ... Sickle Cell Disease (SCD) is a disorder of the red blood cells, which can ...
(Date:6/24/2016)... MIAMI, Fla. (PRWEB) , ... June 24, 2016 , ... ... Florida Trend magazine’s 2016 Legal Elite. The attorneys chosen by their peers for this ... of Florida. , Seven Greenberg Traurig Shareholders received special honors as members of this ...
(Date:6/24/2016)... ... ... Inc, makers of Topricin and MyPainAway Pain Relief Products, join The ‘Business for a Fair ... hour by 2020 and then adjusting it yearly to increase at the same rate as ... the wage floor does not erode again, and make future increases more predictable. , The ...
(Date:6/24/2016)... NY (PRWEB) , ... June 24, 2016 , ... ... Haute Living, is proud to recognize Dr. Barry M. Weintraub as a prominent ... “the most beautiful women in the world, and the most handsome men, look ...
Breaking Medicine News(10 mins):
(Date:6/24/2016)... --  Pulmatrix, Inc ., (NASDAQ: PULM ), ... today that it was added to the Russell Microcap ... set of U.S. and global equity indexes on June ... for Pulmatrix," said Chief Executive Officer Robert Clarke ... in developing drugs for crucial unmet medical needs, and ...
(Date:6/23/2016)... June 23, 2016  MedSource announced today that ... e-clinical software solution of choice.  This latest decision ... value to their clients by offering a state-of-the-art ... relationship establishes nowEDC as the EDC platform of ... full-service clients.  "nowEDC has long been a preferred ...
(Date:6/23/2016)... , June 23, 2016 Research ... "Pharmaceutical Excipients Market by Type (Organic Chemical (Sugar, Petrochemical, ... (Oral, Topical, Coating, Parenteral) - Global Forecast to 2021" ... The global pharmaceutical excipients market is ... a CAGR of 6.1% in the forecast period 2016 ...
Breaking Medicine Technology: